Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
As of 3:35:16 pm GMT-5. Market Open.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback